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Summary
Triple negative breast cancer is an aggressive form of breast cancer. Despite treatment with
chemotherapy, relapses are frequent and response to these treatments is not the same in
younger women as in older women. Therefore, the identification of genes that cause this
difference is required. The identification of therapeutic targets is one of the sought after
goals to develop new drugs. Within the range of different hybridization techniques, the
developed system uses expression array analysis to measure the expression of the signal
levels of thousands of genes in a given sample. Probesets of Gene 1.0 ST GeneChip arrays
provide categorical genome transcript coverage, providing a measurement of the expres-
sion level of the sample. This paper proposes a multi-agent system to manage information
of expression arrays, with the goal of providing an intuitive system that is also extensible to
analyze and interpret the results. The roles of agent integrate different types of techniques,
statistical and data mining methods that select a set of genes, searching techniques that find
pathways in which such genes participate, and an information extraction procedure that
applies a CBR system to check if these genes are involved in the disease.
1 Introduction
Triple negative breast cancer (TNBC) is a form of cancer in which none of the three most com-
mon types of receptors (estrogen, progesterone, and the HER-2 / neu gene) usually present in
other breast cancers. This means that breast cancer cells tested negative for hormone epidermal
growth factor receptor 2 (HER-2), estrogen receptor (ER) and progesterone receptor (PR) [1].
For this reason, common treatments such as hormone therapy and drugs that target these three
receptors are ineffective. To improve the treatment of this cancer we must attempt to understand
the possible role played by genes that affect younger patients and older patients differently. To
this end, drugs that enhance the therapeutic efficacy of current methods are currently being
sought.
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There are several techniques that can be used to study genetic variation in patients, such as
tissue microarrays, expression arrays (RNA) [2, 3], genomic arrays (DNA) and arrays of mi-
croRNAs (miRNAs). Arrays used in the study of expression profiling are cDNA arrays and
oligonucleotide chips. Moreover, different types of genomic arrays (DNA) are used, includ-
ing BAC aCGH, oligo CGH, SNP CGH and aCGH (Comparative Genomic Hybridization) [4].
CGH arrays (aCGH) can compare the DNA of a patient with control DNA and use this infor-
mation to detect mutations [5, 6] based on the increase, loss or amplifications [7] in different
regions of the chromosome. There are new exon arrays that provide accurate assessments of
gene expression [8]. Information sources are varied but laboratory personnel usually follow
fixed analysis processes that are distributed in sequences, which are in turn executed repeatedly
in the search for genes that are considered to be relevant. Therefore, it is necessary to find a
system that automates this process so that the work of the laboratory staff is simplified.
There have also been efforts to provide a solution to the main challenges associated with ana-
lyzing microarray data, which are: the high amount of data (coming from thousands of genes
extracted from few samples); the high complexity of the data; the fact that gene datasets in
microarrays are often correlated (either directly or indirectly); and the fact that most gene se-
lection and prediction models emphasize the capacity for effective classification instead of the
function of an effective selection. The assumption is that statistical significance is equivalent to
biological importance.
There are other investigations which focus their efforts in predicting genes that cause diseases.
Thanh-Phuong Nguyne and Tu-Bao Ho have developed a semi-supervised framework in order
to find genes and detect possible connections among those that can lead to diseases [9]. They
are based on feature extraction, and preprocessing of data and integrate the following resources:
Universal ProteinResource (UniProt) [10] Gene Ontology (GO) [11], Pfam [12], InterDom
[13], Reactome [14] and expression datasets [15]. Maglietta et al. [16] propose a method
from a similar point of view. The target is the selection of genes relevant to a pathology by
analysing the tissue expression profiles for two different phenotypic conditions. Statistical
techniques are used and the presence of genes in similar studies is verified. Other studies
use multiagent systems in order to analyze array data, including a system proposed by Juan
F. De Paz et al. [17], where a multiagent system analyses CGH arrays searching for gene
gains or losses, which are then represented. This study is more oriented to obtain relevance
areas and provide easy access to information but works only with CGH arrays. The present
paper proposes a multi-agent system to analyze expression arrays. The main novelty is that the
system can learn analysis flows (workflow) while the expression analysis is being performed,
thus automating the analysis of expression. During the analysis, services are incorporated in
order to carry out the analysis and extraction of information from databases, through which the
most relevant genes are selected. Different data mining techniques and databases were used to
analyse expression profiles and obtain relevant genes for two different phenotypic conditions.
The system was applied to a real case study for the analysis of breast cancer with the aim of
analysing differences in this type of cancer with specific regard to the patients age.
This article is organized as follows: section 2 describes the state of the art of expression arrays,
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2 Gene Expression Arrays
Microarrays constitute a widely used tool that measure gene expression [18]. Moreover, this
technology has attracted special interest in cancer research [19]. An expression arrays analysis
makes it possible to study and compare transcriptomes of different samples. The value of gene
expressions in these biochips is determined by the intensity of the hybridization of transcripts
with a group of probes [8].
With these qualities, expression arrays become a very useful tool that makes it possible to
determine which genes have an altered expression, to compare expressions based on certain
parameters, and to diagnose and distinguish subtypes of cancers with similar clinical manifes-
tations, among other things. Different kinds of cancer genes share groups and altered pathways.
Array analysis can investigate typical genes, as well as those that are not common to the vast
majority of proliferative syndromes [18], existing in more specific forms of the disease. This is
one factor that makes arrays a useful diagnostic tool.
Beyond studying the expression of each gene and its degree of responsibility in an alteration, it
is vital to understand the expression of these genes and the proteins they encode in the context
of signaling pathways [20].
To be able to perform a complete analysis, one of the roles of a multi-agent system is to search
in different databases for the pathways taken by the specific genes that are being studied. One
mutation in a particular gene can give rise to various effects, even in the same type of tissue [21].
Because of this, the function of the platform is interesting, specifically because the information
obtained from the study of a single gene is not representative if, after it has been studied, its
relationship to other elements that also influence the signaling pathway is not verified [20].
The main function of this platform is to be able to select the relevant genes for the investigation.
There comes a point during the screening process when there is no longer a sufficient number
of elements to obtain pathways. It is precisely for this reason, from a research point of view,
that it is important to compare the genes obtained from the analysis that best explain the gene
alteration (depending on the studied parameter) according to the altered pathways.
Among the most influential resulting gene expression analyses of patient samples in our case
study, those that are also therapeutic targets are of particular interest to medical research. One
of the great difficulties of the analysis of arrays is to obtain biologically valid conclusions from
vast amounts of data [22]. Consequently, one agent from the multi-agent system is responsible
for conducting searches in databases known to contain therapeutic targets: TTB (Therapeutic
Target Database) [23] and DrugBank [24]. This opens up the possibility of attacking these
targets with drugs and conducting pharmacogenomic research after the analysis [18]. This
makes it possible to check and directly study the influence of the pathway in the carcinogenic
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3 Multi-agent System
In these studies, users have to work with a large volume of information, which involves the
development of programs to improve data analysis systems and to automatically extract infor-
mation through databases [25].
Our study uses expression arrays that determine the expression of genes to the probes used.
This information is taken into account to observe differences that may occur in the same genes
with regard to the age factor. Because large amounts of data are handled, it is necessary to
develop a system aimed at simplifying the management and analysis of this information, and
at automatically extracting information to determine the correlation of these genes in breast
cancer.
Distributed analysis of expression data is performed by various laboratory personnel: from
chip hybridization to the removal of variations and irelevant information associated with the
chips. This study shows a multiagent system specifically designed, with an abstract architec-
ture for this virtual organizations [26], to analyze expression arrays. The functionality of the
multi-agent system is divided into layers and roles to perform the analysis, which usually con-
sists of several stages. The first stage is preprocessing, which performs the important task of
removing probes without notation and screening the data for the first time. The next stage per-
forms an analysis of the expression probes (Non-parametric statistical test like Mann-Whitney
or Kruskal-Wallis), searching for differences with respect to the expression under normal con-
ditions for that gene, or with respect to any specific factor. This test are applied to obtain the
genes for testing the proposed statistical hypothesis. In the next stage data mining techniques
are applied, allowing the data set studied to be further reduced. When looking for differences
between groups of patients, it is important to confirm whether a cluster has been properly
formed at the end of this stage, according to the case study. If a suitable result is not obtained,
it will be necessary to review the previous step of extracting relevant genes through the data
mining techniques. The final stage is initiated once the data set containing the different genes
has been identified. This data set will be transferred to a database that checks the implication
of these genes in the specific disease being studied to determine whether there is a relationship.
The gen notation and pathways in which most of these genes develop their biological activity
is obtained.
JADE (Java Agent DEvelopment Framework) was adopted for the design and implementation
of the proposed intelligent multi-agent. The architecture is composed of four layers: Analysis,
Information Management, Visualization and Workflow. The architecture is shown in Fig. 1.
The workflow layer includes an agent in charge of workflow in the other layers, and of estab-
lishing the correct order for the activity of each agent. Workflow analysis collects information
about the settings and can repeat the sequences performed above for expression analysis. This
aspect makes it possible to automate repetitive analysis tasks for laboratory personnel.
The analysis layer performs microarray analysis tasks as required by the process. This layer
consists of several agents that are responsible for implementing the necessary processes and al-
gorithms. An agent applies the Entropy-based filters, which are responsible for finding discrete
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Figure 1: Multi-agent System Arquitecture
plies the nonparametric Mann-Whitney statistical test to two independent samples. One more
agent applies a normalization to adjust the signal, which may contain errors caused by technical
and / or biological factors. The normalization technique applied is RMA (Robust multiarray
Average), which adjusts information on each probeset to a comparable value. If any is over-
expressed or under-expressed its genetic value is regulated with regard to the total. Another role
performed by a system agent is the elimination of control probes and probes without notation.
Finally, another agent produces a dendrogram that allows us to organize data into subcategories
(younger and elderly patients) in which the case study is divided. This representation enables a
clear representation of the relationship between data grouping.
The information management layer is responsible for confirming whether the genes obtained
from the results of the analysis layer are related to the type of cancer that are the focus in the
case study. This layer creates a database that collects the learned genes that are related to a
cancer that is not contained in the databases used for the visit; this database is also queried in
the process of relating genes to the cancer in the case study. This layer also includes an Agent
that collects the annotation and other information for each resulting gene and the agent that
retrieves the pathways associated with these genes.
The display layer shows the pathway associated with the result as well as the list of the im-
plicated genes. This layer also manages the pathway visualization, showing the pathway as-
sociated with the gene list obtained. The gene list is sent using the KEGG Mapper (http:
//www.genome.jp/kegg/tool/map_pathway1.html). A pathway can be disrupted
by a mutation on a single gene. The multi-agent system selects the pathways which present
several changes in the pathology due to age factor. The selected pathways are shown.The dis-
play layer manages the case based reasoning (CBR) system doing the four-step process. Once a
relevant case is retrieved, that workflow is reused in the new problem with a previous adaptation
as needed to fit the new problem. Later, the revise step is performed to avoid undesired steps in
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Figure 2: Tipical Workflow
Once an analysis of the input data has been performed, the CBR retrieves a relevant case of
previous studies from the memory workflow. The CBR is based on the type of input variable
(nominal or categorical qualitative);an analysis is performed for the other variable, the level
of expression. Once one of the workflows to reuse is selected, the solution is reviewed and
changes are made in the value of the test variable to the hypothesis if considered appropriate,ie
the p-value of the used statistical method. If the applied workflow is considered a satisfactory
solution, the corresponding activities are carried out with the respective values of the variables
to be applied in posterior analysis. This process can be seen in Fig. 2. The implemented
workflow can follow the same steps as the typical process of Fig. 3.
4 Results
The case study was performed with 16 samples from patients with triple negative breast cancer
provided by the Salamanca Cancer Institute. 8 samples corresponded to younger patients (less
than 45 years) and the remaining 8 samples to elderly patients (over 68 years). Additional
samples continue to be gathered in order to improve the accuracy of the results.
The technology used to analyze the microarray was Affymetrix, which is based on oligonu-
cleotide chips. The specific chip used was the HuGene-1.0st-v1 chip, which contains 33,297
probes that identify about 23,000 sequenced genes.
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Figure 3: CBR Workflow
the samples of these patients. The goal is to obtain genes that show differences between samples
from younger patients and older patients in order to discover why older women respond better
to the treatment.
The first step in the analysis of oligonucleotide chips is the process of discarding any control
probes and probes without notation. Once these probes are discarded a denormalization process
[27] is performed. This process discards the values that deviate from the normal value, and
applies the statistic test (Mann-Whitney) to each of the independent samples used in the case
study (younger women and older women). In that step a Benjamini and Hochberg FDR multiple
test correction is performed and applied on the p-value, calculated based on the two-samples
Mann-Whitney samples.
In our case of study, we look for variations that may occur in the expression levels of genes
for samples associated with younger women compared with those of the older women. Once
applied, we discard all values exceeding a p-value greater than 0.01, i.e., we keep the probes that
have a greater interest because of their expression level compared with older youth at statistical
level.
In this process of data analysis, once the preprocessing, normalization and application of statis-
tical tests and techniques of data mining are completed, a clustering algorithm is applied. This
algorithm provides us with a dendrogram which allows us to check the degree of clustering of
the probes with respect to the two samples (probes for younger and older women). Process
results are shown in Fig. 4. The next stage is responsible for managing information received
from the data obtained at the end of the analysis stage. These genes are contrasted with the
corresponding type of cancer data base with which the data are associated (in this case study,
the data base is for breast cancer). With this process we discard genes that are not implicated in
a certain cancer, focusing on those that are. The pertinent notation and associated pathways are
obtained for this final gene set, allowing the access and use of this information. The workflow
layer agent learns the execution sequence of tasks, the order in which the agents interact with
each other to execute the various processes and algorithms. With this initial learning, the fol-
lowing analysis of expression arrays is performed automatically, so the lab technicians do not
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Figure 4: Resulting Dendogram and Heatmap
lower yield.
Once the genes and pathways are shown, an agent from the visualization layer performs a
reasoning cycle (CBR). During information from the catalogued gene is obtained from the
accurate database G2SBC (Genes-to-Systems Breast Cancer Database - http://www.itb.
cnr.it/breastcancer/). While contrasting genes with the breast cancer database, these
genes are evaluated according to the contrast hypothesis mentioned in part 3. In this way, if our
system detects genes which are not in the databases and influence the pathology according to
the results, those genes are stored in their own database for future analysis.
Table 1. shows the most important genes obtained in the case study for triple negative breast
cancer. These genes are considered by the system as the most important with regards to differ-
ences in response to treatment of younger women and older women.
There was no pathway in which two or more selected genes were present. However, this is not
surprising since the final number of genes kept is very small in order to provide a manageable
quantity for the researcher. Although it is well known that expression varies with aging, there
are few simultaneous gene relationships between age and breast cancer at the same time that
have been previously described in literature.
We have obtained five relevant genes in TNBC presenting expression changes due to age factor.
The Sfrp1 gene (Secreted frizzled-related protein 1) can be interesting in this case because its
regulator role of the Wnt pathway which can be seen in Fig. 5, regulates growth and differenti-
ation in different cell types. The protein encoded by this gene has a direct inhibitory effect on
Wnt proteins. This ultimately leads to the inhibition of proliferation in vascular cells, and also
delays the G1 cycle phase in these same cells [28].
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Table 1: Resulting altered genes
Altered genes with close relationship Altered genes with no-apparent relation
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in our TNBC patient samples. Although SFRP1 loss is most notable with age, this mutation
occurs early in tumor development, so damage caused by this impairment is not unique to
advanced age patients In fact, it has been suggested that this could be a prognosis marker of
patients with breast cancer in early stages [31]. SFRP1 expression has been associated with
a greater chance of a positive response to neoadjuvant chemotherapy [32]. Furthermore, it
has been found that this loss of mRNA is reflected in a remarkable effect on protein loss. By
interfering with this gene expression, it has been found that Wnt pathway becomes active in
hepatoma [33]. Therefore, due to its reduced expression levels in the disease, SFRP1 could not
exert an inhibitory effect in Wnt in order to control proliferation. However, this is not the only
interpretation to date. Bernemann et al. suggest in their study that the invasion of tumor cells
is not really regulated by the Wnt pathway in TNBC, but through other pathways [32].
Retinoic acid (active form of vitamin A) binds to RARB, which is involved in cell signaling
processes such as morphogenesis, differentiation and cell growth. Loss of retinoic acid re-
ceptor in breast cancer has been described previously [34]. This receptor mediates the growth
inhibitory effect exerted by retinoic acid, due to its apoptosis-promoting action. For this reason,
the underexpression of the RARB gene may be favoring the uncontrolled growth of tumor cells.
The involvement of GABA A receptor subunit pi (GABRP) in breast cancer has not been well
defined. However it is noteworthy that it is detectable in many non-neural tissues. Furthermore,
it has been observed that with patients in which brain metastasis occurs, there is a considerable
increase in GABA A receptor levels so it is also a prognostic marker. Its reinforcing role
has been demonstrated in tumor cell lines [35] and it is a potential therapeutic target. In the
sample of patients used in this study GABRP expression decreases with age. This result seems
consistent with the described lower survival when this gene is overexpressed.
MID1 is part of the tripartite motif. This gene expression was higher in the group of elderly
patients in our case study. MID1 is a negative regulator of tumor suppressor PP2A, in the
mTOR pathway. Consequently, its overexpression is affecting proliferation, contributing to
uncontrolled division.
The multiagent identified GABA A and RARB as registered therapeutic targets, increasing their
interest in what regards to pharmacogenomics. However, to better appreciate the usefulness of
resulting genes that are themselves therapeutic targets, it is necessary tocheck if the gene in
question is over or under-expressed. Although GABA A and RARB are registered as targets,
blocking them is not appropriate from a therapeutic point of view, since the alteration consists
precisely in an expression decrease. However, the use of drugs on these targets could have great
scientific interest in order to study the involvement of each alteration in cancer and its relative
importance.
Although MID1 has not been registered as a target yet, several authors have suggested that this
is a promising [36] therapeutic target, and it would be interesting to find an appropiate drug.
In fact, this gene is more suitable for the subsequent investigation, considering its role and, as
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5 Conclusions
The developed system enables using patient samples to know if there are differences in the
expression level for the proposed gene sets, allowing the system to return the genes that produce
differences in the samples with regard to the associated notation and pathways in which are
implicated.
This case study looked at the differences in expressions that can occur in female patients
younger than 50 years of age compared with those older than 50, since the latter group respond
better to the treatments used.
This study is interesting because finding genes that behave differently can lead to new informa-
tion and the possibility of adjusting treatments for this type of cancer in younger patients.
The multi-agent system is developed in a way that allows new agents to be inserted with new
techniques or existing data to be modified for analysis and facilitates data analysis. The sys-
tem provides access to various databases so different cancer datasets can be introduced. The
system uses a CBR that handles all information obtained from the databases and allows the
incorporation of new information that may be used in future analysis.
In conclusion, it is noteworthy that genes obtained in this case study from using our tool are
suitable for pharmacogenomics research because of their influence on tumor processes in breast
cancer.
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